BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Powell HR, Davidson PM, Mccredie DA, Phair P, Walker RG. Haemolytic‐uraemic syndrome after treatment with metronidazole. Medical Journal of Australia 1988;149:222-3. [DOI: 10.5694/j.1326-5377.1988.tb120578.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Chua K, Howden B. Metronidazole. Kucers' The Use of Antibiotics Sixth Edition. CRC Press; 2010. pp. 1211-37. [DOI: 10.1201/b13787-103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Situnayake RD, Crump BJ, Thurnham DI, Taylor CM. Further evidence of lipid peroxidation in post-enteropathic haemolytic-uraemic syndrome. Pediatr Nephrol 1991;5:387-92. [DOI: 10.1007/bf01453659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Ruggenenti P, Remuzzi G. The pathophysiology and management of thrombotic thrombocytopenic purpura. European Journal of Haematology 1996;56:191-207. [DOI: 10.1111/j.1600-0609.1996.tb01930.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 3.1] [Reference Citation Analysis]
4 Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial 2004;8:102-11. [PMID: 15255125 DOI: 10.1111/j.1526-0968.2003.00127.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 63] [Article Influence: 4.7] [Reference Citation Analysis]
5 Crosara SL, Qumari S, Wall GC, Belz MM. Mitomycin-C-Induced Thrombotic Thrombocytopenic Purpura. Journal of Pharmacy Practice and Research 2013;43:221-4. [DOI: 10.1002/j.2055-2335.2013.tb00259.x] [Reference Citation Analysis]
6 Nir I. Antiprotozoal drugs. Elsevier; 1991. pp. 286-307. [DOI: 10.1016/s0378-6080(05)80332-0] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
7 Ruggenenti P, Remuzzi G. Thrombotic microangiopathies. Critical Reviews in Oncology/Hematology 1991;11:243-65. [DOI: 10.1016/1040-8428(91)90028-b] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Lau AH, Lam NP, Piscitelli SC, Wilkes L, Danziger LH. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992;23:328-64. [PMID: 1478003 DOI: 10.2165/00003088-199223050-00002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 111] [Article Influence: 4.8] [Reference Citation Analysis]
9 Holloway S, Senior D, Roth L, Tisher CC. Hemolytic Uremic Syndrome in Dogs. Journal of Veterinary Internal Medicine 1993;7:220-7. [DOI: 10.1111/j.1939-1676.1993.tb01011.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rivkin A. Thrombotic thrombocytopenic purpura induced by metronidazole vaginal gel. Pharmacotherapy 2007;27:1058-61. [PMID: 17594212 DOI: 10.1592/phco.27.7.1058] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
11 Goodman DJ, Walker RG, Birchall IE, d'Apice AJ, Powell HR, Kincaid-Smith P. Recurrent haemolytic uraemic syndrome in a transplant recipient on orthoclone (OKT 3). Pediatr Nephrol 1991;5:240-1. [PMID: 1903267 DOI: 10.1007/BF01095964] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Orion E, Matz H, Wolf R. The life-threatening complications of dermatologic therapies. Clinics in Dermatology 2005;23:182-92. [DOI: 10.1016/j.clindermatol.2004.06.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]